To our knowledge, this study is one of few that compare clinical outcomes and medication costs for patients with type 2 diabetes converted from insulin glargine to insulin detemir indicated for basal blood glucose control reflecting real-world results. This evidence concerns the gene INS and type 2 diabetes mellitus.